Stephen Gruber
Has grant
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Integration of epidemiology, pathology, immunology and outcomes in colorectal cancer
Open Date: 2022-09-22
Close Date: 2027-08-31
Grant: Close
Precision Approaches to Refining TP53-associated Cancer Risk
Open Date: 2019-09-01
Close Date: 2024-08-01
Grant: Close
The Epidemiology of Immune Responses in Colorectal Cancer
Open Date: 2015-08-01
Close Date: 2020-07-31
Grant: Close
Cancer Genetics Professional Education in a Global Community of Practice
Open Date: 2013-09-01
Close Date: 2023-08-01
Grant: Close
Translational Research in GI Cancer
Open Date: 2010-09-13
Close Date: 2017-08-31
Articles (31)
Year:
2026
Introduction There is convincing evidence that overall adiposity increases the risks of several cancers. Whether the distribution of adiposity plays a similar role is unclear. Methods We used 2-sample Mendelian randomization (MR) to examine causal relationships of 5 adiposity distribution traits (abdominal subcutaneous adipose tissue (ASAT); visceral adipose tissue (VAT); gluteofemoral adipose tissue (GFAT); liver fat; and pancreas fat) with the risks of 12 obesity-related cancers (endometrial, ovarian, breast, colorectal, pancreas, multiple myeloma, liver, kidney (renal cell), thyroid, gallbladder, esophageal adenocarcinoma, and meningioma). Results Sample size across all genome-wide association studies (GWAS) ranged from 8407 to 728 896 (median: 57 249). We found evidence that higher genetically predicted ASAT increased the risks of endometrial cancer, liver cancer, and esophageal adenocarcinoma (odds ratios (OR) and 95% confidence intervals (CI) per standard deviation (SD) higher ASAT = 1.79 (1.18 to 2.71), 3.83 (1.39 to 10.53), and 2.34 (1.15 to 4.78), respectively). Conversely, we found evidence that higher genetically predicted GFAT decreased the risks of breast cancer and meningioma (ORs and 95% CIs per SD higher genetically predicted GFAT = 0.77 (0.62 to 0.97) and 0.53 (0.32 to 0.90), respectively). We also found evidence for an effect of higher genetically predicted VAT and liver fat on increased liver cancer risk (ORs and 95% CIs per SD higher genetically predicted adiposity trait = 4.29 (1.41 to 13.07) and 4.09 (2.29 to 7.28), respectively). Discussion Our analyses provide novel insights into the relationship between adiposity distribution and cancer risk. These insights highlight the potential importance of adipose tissue distribution alongside maintaining a healthy weight for cancer prevention.
Year:
2025
Supplementary Figure S5 shows the age-stratified calibration on 5- and 10-year absolute risks based on the PRS-enhanced model stratified by deciles of predicted risk in GERA European ancestry participants.
Year:
2025
Supplementary Figure S4 shows the family-history-stratified calibration on 5- and 10-year absolute risks based on the PRS-enhanced model stratified by deciles of predicted risk in GERA European ancestry participants.
Year:
2025
Background: Currently known associations between common genetic variants and colorectal cancer explain less than half of its heritability of 25%. As alcohol consumption has a J-shape association with colorectal cancer risk, nondrinking and heavy drinking are both risk factors for colorectal cancer. Methods: Individual-level data was pooled from the Colon Cancer Family Registry, Colorectal Transdisciplinary Study, and Genetics and Epidemiology of Colorectal Cancer Consortium to compare nondrinkers (≤1 g/day) and heavy drinkers (>28 g/day) with light-to-moderate drinkers (1–28 g/day) in GxE analyses. To improve power, we implemented joint 2df and 3df tests and a novel two-step method that modifies the weighted hypothesis testing framework. We prioritized putative causal variants by predicting allelic effects using support vector machine models. Results: For nondrinking as compared with light-to-moderate drinking, the hybrid two-step approach identified 13 significant SNPs with pairwise r 2 > 0.9 in the 10q24.2/ COX15 region. When stratified by alcohol intake, the A allele of lead SNP rs2300985 has a dose–response increase in risk of colorectal cancer as compared with the G allele in light-to-moderate drinkers [OR for GA genotype = 1.11; 95% confidence interval (CI), 1.06–1.17; OR for AA genotype = 1.22; 95% CI, 1.14–1.31], but not in nondrinkers or heavy drinkers. Among the correlated candidate SNPs in the 10q24.2/ COX15 region, rs1318920 was predicted to disrupt an HNF4 transcription factor binding motif. Conclusions: Our study suggests that the association with colorectal cancer in 10q24.2/ COX15 observed in genome-wide association study is strongest in nondrinkers. We also identified rs1318920 as the putative causal regulatory variant for the region. Impact: The study identifies multifaceted evidence of a possible functional effect for rs1318920.
Year:
2025
Background: Tobacco smoking is an established risk factor for colorectal cancer. However, genetically defined population subgroups may have increased susceptibility to smoking-related effects on colorectal cancer. Methods: A genome-wide interaction scan was performed including 33,756 colorectal cancer cases and 44,346 controls from three genetic consortia. Results: Evidence of an interaction was observed between smoking status (ever vs. never smokers) and a locus on 3p12.1 (rs9880919, P = 4.58 × 10 −8 ), with higher associated risk in subjects carrying the GG genotype [OR, 1.25; 95% confidence interval (CI), 1.20–1.30] compared with the other genotypes (OR P = 1.72 × 10 −8 ) and 8q24.23 (rs7005722, P = 2.88 × 10 −8 ). Subjects carrying the rs4151657 TT genotype showed higher risk (OR, 1.12; 95% CI, 1.09–1.16) compared with the other genotypes (OR CADM2 (3p12.1) and ATF6B (6p21.33). Conclusions: Our study identified novel genetic loci that may modulate the risk for colorectal cancer of smoking status and intensity, linked to tumor suppression and immune response. Impact: These findings can guide potential prevention treatments.
Year:
2025
Supplementary Figure S2 shows the sex-stratified calibration on 5- and 10-year absolute risks based on the PRS-enhanced model stratified by deciles of predicted risk in GERA European ancestry participants.
Year:
2025
Background: Mechanistic data indicate the benefit of short-chain fatty acids (SCFA) produced by gut microbial fermentation of fiber on colorectal cancer, but direct epidemiologic evidence is limited. A recent study identified SNPs for two SCFA traits (fecal propionate and butyrate-producing microbiome pathway PWY-5022) in Europeans and showed metabolic benefits. Methods: We conducted a two-sample Mendelian randomization analysis of the genetic instruments for the two SCFA traits (three SNPs for fecal propionate and nine for PWY-5022) in relation to colorectal cancer risk in three large European genetic consortia of 58,131 colorectal cancer cases and 67,347 controls. We estimated the risk of overall colorectal cancer and conducted subgroup analyses by sex, age, and anatomic subsites of colorectal cancer. Results: We did not observe strong evidence for an association of the genetic predictors for fecal propionate levels and the abundance of PWY-5022 with the risk of overall colorectal cancer, colorectal cancer by sex, or early-onset colorectal cancer (diagnosed at P = 0.03) but it did not surpass multiple testing of subgroup analysis. Conclusions: Genetic instruments for fecal propionate levels and the abundance of PWY-5022 were not associated with colorectal cancer risk. Impact: Fecal propionate and PWY-5022 may not have a substantial influence on colorectal cancer risk. Future research is warranted to comprehensively investigate the effects of SCFA-producing bacteria and SCFAs on colorectal cancer risk.
Year:
2025
Background: Polygenic risk scores (PRS) which summarize individuals’ genetic risk profile may enhance targeted colorectal cancer screening. A critical step towards clinical implementation is rigorous external validations in large community-based cohorts. This study externally validated a PRS-enhanced colorectal cancer risk model comprising 140 known colorectal cancer loci to provide a comprehensive assessment on prediction performance. Methods: The model was developed using 20,338 individuals and externally validated in a community-based cohort ( n = 85,221). We validated predicted 5-year absolute colorectal cancer risk, including calibration using expected-to-observed case ratios (E/O) and calibration plots, and discriminatory accuracy using time-dependent AUC. The PRS-related improvement in AUC, sensitivity and specificity were assessed in individuals of age 45 to 74 years (screening-eligible age group) and 40 to 49 years with no endoscopy history (younger-age group). Results: In European-ancestral individuals, the predicted 5-year risk calibrated well [E/O = 1.01; 95% confidence interval (CI), 0.91–1.13] and had high discriminatory accuracy (AUC = 0.73; 95% CI, 0.71–0.76). Adding the PRS to a model with age, sex, family and endoscopy history improved the 5-year AUC by 0.06 ( P P = 0.05) in the screening-eligible age and younger-age groups, respectively. Using a risk-threshold of 5-year SEER colorectal cancer incidence rate at age 50 years, adding the PRS had a similar sensitivity but improved the specificity by 11% ( P P = 0.04) with similar specificity. Conclusions: The proposed PRS-enhanced model provides a well-calibrated 5-year colorectal cancer risk prediction and improves discriminatory accuracy in the external cohort. Impact: The proposed model has potential utility in risk-stratified colorectal cancer prevention.
Year:
2025
Supplementary Figure S3 shows the endoscopy-history-stratified calibration on 5- and 10-year absolute risks based on the PRS-enhanced model stratified by deciles of predicted risk in GERA European ancestry participants.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (91)
Li Hsu
Fred Hutchinson Cancer Research Center
Polly Newcomb
University of Washington
Marc Gunter
International Agency for Research on Cancer
Tabitha Harrison
Fred Hutchinson Cancer Research Center
Konstantinos K. Tsilidis
-
Victor Moreno
Professor
University of Barcelona
Marina Evangelou
Senior Lecturer in Statistics
Imperial College London
Emma Vincent
Academic , Professor of Molecular Metabolism
University of Bristol
Fränzel J.B. van Duijnhoven
Wageningen University & Research
Xiao‐Ou Shu
Vanderbilt University Medical Center
Susanna Larsson
Professor at Karolinska Institutet
Karolinska Institutet
Juan Pablo Lewinger
Associate Professor
University of Southern California
John Baron
Professor
University of North Carolina
David Drew
Assistant Professor of Medicine
Massachusetts General Hospital
Peter Georgeson
University of Melbourne
Qingrun Zhang
Assistant Professor
University of Calgary
Ulrike Peters
Fred Hutchinson Cancer Research Center
Jihyoun Jeon
University of Michigan
Yin Cao
Washington University School of Medicine
Zhaozhong Zhu
Massachusetts General Hospital
Matthew Devall
Assistant Professor
University of Virginia
Sophia Harlid
Umea University
Eric Kawaguchi
Assistant Professor
University of Southern California
Julie R Palmer
Boston University School of Medicine
Lisa Boardman
Professor of Medicine
Mayo Clinic
Georgios Markozannes
Assisant professor
Imperial College London
Wei Zheng
-
Weiqiang Lin
Professor
Zhejiang University
Elizabeth Platz
Professor
Johns Hopkins University
Yingye Zheng
Fred Hutchinson Cancer Research Center
Mariana C. Stern
Professor
University of Southern California
Qiuyin Cai
Professor
Vanderbilt University Medical Center
Christos V. Chalitsios
University of Oxford
Ludmila Vodickova
senior researcher
Charles University
Tim Bishop
University of Leeds
Ran Tao
Associate Professor
Vanderbilt University Medical Center
Elizabeth Hauser
Duke University
GUOCHONG JIA
Vanderbilt University
Richard Hayes
Professor of Population Health and Environmental Medicine
NYU School of Medicine
Mingyang Song
Associate Professor
Harvard University
Stéphane Bézieau
Université de Nantes
Giovanni Parmigiani
Professor
Dana-Farber Cancer Institute
Virginia Díez-Obrero
Vrije Universiteit Amsterdam
Hongmei Nan
Professor
University of Indianapolis
Zhishan Chen
staff Scientist
Vanderbilt University
Sun-Seog Kweon
Chonnam National University
Kaitlin Wade
Associate Professor in Epidemiology
University of Bristol
Emmanouil Bouras
Research associate
Imperial College London
Alicja Wolk
Professor of Nutritional Epidemiology
Karolinska Institutet
Anna H. Wu
Professor
University of Southern California
Robert C. Grant
University Health Network
John Potter
Professor
University of Washington
Xingyi Guo
Associate Professor
Vanderbilt University Medical Center
Bethany Van Guelpen
Umea University
Li Li
University of Virginia
Iris Lansdorp-Vogelaar
Associate Professor
Erasmus University Medical Center
Philip Haycock
Senior Lecturer in Cancer Epidemiology
University of Bristol
Xia Jiang
Karolinska Institutet
Jirong Long
Professor
Vanderbilt University Medical Center
Andrea Burnett-Hartman
Epidemiologist Program Director
Fred Hutchinson Cancer Research Center
Wei Sun
Professor
Fred Hutchinson Cancer Research Center
Andrea Gsur
Medical University of Vienna
Gianluca Severi
University of Firenze
Loic Le Marchand
Professor
University of Hawaii
Edward A. Ruiz-Narváez
Associate Professor
University of Michigan School of Public Health
Elom K Aglago
Imperial College London
David Conti
Professor
Colorado School of Public Health
W. James Gauderman
professor
University of Southern California
Vicente Martín-Sánchez
JEFE DE GRUPO
Universidad de León
Paul Pharoah
Professor of Cancer Epidemiology
Cedars-Sinai Medical Center
Graham Casey
University of Virginia
Yaohua Yang
Assistant Professor
University of Virginia
Catherine Tangen
Fred Hutchinson Cancer Research Center
Satu Männistö
Finnish Institute for Health and Welfare
Kala Visvanathan
Professor
Johns Hopkins University
Jessica Petrick
Boston University
Daniel D. Buchanan
Senior Research Fellow
University of Melbourne
Michelle Cotterchio
Professor (status only)
University of Toronto
Christopher Li
Fred Hutchinson Cancer Research Center
Annika Lindblom
Karolinska Institutet
Jochen Hampe
Scientific Speaker
Technische Universität Dresden
Anshul Kundaje
Associate Professor
Stanford University
Mark Jenkins
University of Melbourne
Peter T. Campbell
Professor
Albert Einstein College of Medicine
Graham Giles
Head of Research
-
Michael Hoffmeister
Professor of Epidemiology, Group leader, Deputy divison head
German Cancer Research Center (DKFZ)
Amanda Toland
Ohio State University
Volker Arndt
Group leader
Deutsches Krebsforschungszentrum
Elizabeth Barry
Associate Professor
Dartmouth College Geisel School of Medicine
Pavel Vodička
senior researcher
Charles University
Jennifer Ose
Professorin (W2)
Hochschule Hannover
Make your next move.
Prepare your application
Review drafts before you send them.